Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker

Journal of Proteomics

Volumn 75, Issue 3, 2012, Pages 833-844

  Hosako, Mutsumi ^a   Muto, Taika ^a   Nakamura, Yukiko ^a,b   Tsuta, Koji ^b   Tochigi, Naobumi ^a   Tsuda, Hitoshi ^b   Asamura, Hisao ^b   Tomonaga, Takeshi ^c   Kawai, Akira ^b   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Biomarker; Laser microdissection; Malignant pleural mesothelioma; Two dimensional difference gel electrophoresis

Indexed keywords

CALRETININ; CATHEPSIN D; CELL PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ELECTROPHORESIS; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT PLEURAL MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SYNOVIAL SARCOMA; TISSUE MICROARRAY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MESOTHELIOMA; NEOPLASM PROTEINS; PLEURAL NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84355161931     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.09.026     Document Type: Article

References (31)

1. Tumours of the lung, pleurs, thymus and heart 2003, International Agency for Research on Cancer (IARC) Press, Lyon.
2. Martino D., Pass H.I. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004, 5:290-298.
3. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
4. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
5. Lindholm P.M., Salmenkivi K., Vauhkonen H., Nicholson A.G., Anttila S., Kinnula V.L., et al. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 2007, 119:46-52.
6. Balsara B.R., Bell D.W., Sonoda G., De Rienzo A., du Manoir S., Jhanwar S.C., et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 1999, 59:450-454.
7. Bjorkqvist A.M., Tammilehto L., Anttila S., Mattson K., Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997, 75:523-527.
8. Wong L., Zhou J., Anderson D., Kratzke R.A. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002, 38:131-136.
9. Yang C.T., You L., Yeh C.C., Chang J.W., Zhang F., McCormick F., et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000, 92:636-641.
10. Schipper H., Papp T., Johnen G., Pemsel H., Bastrop R., Müller K.M., et al. Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas. Int J Oncol 2003, 22:1009-1017.
11. Goto Y., Shinjo K., Kondo Y., Shen L., Toyota M., Suzuki H., et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009, 69:9073-9082.
12. Sugarbaker D.J., Richards W.G., Gordon G.J., Dong L., De Rienzo A., Maulik G., et al. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A 2008, 105:3521-3526.
13. Bidlingmaier S., He J., Wang Y., An F., Feng J., Barbone D., et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009, 69:1570-1577.
14. Hegmans J.P., Veltman J.D., Fung E.T., Verch T., Glover C., Zhang F., et al. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat 2009, 8:323-332.
15. Hegmans J.P., Bard M.P., Hemmes A., Luider T.M., Kleijmeer M.J., Prins J.B., et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol 2004, 164:1807-1815.
16. Menges C.W., Chen Y., Mossman B.T., Chernoff J., Yeung A.T., Testa J.R. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 2010, 1:493-505.
17. Kuramitsu Y., Miyamoto H., Tanaka T., Zhang X., Fujimoto M., Ueda K., et al. Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. Proteomics 2009, 9:5078-5089.
18. Ou W.B., Corson J.M., Flynn D.L., Lu W.P., Wise S.C., Bueno R., et al. AXL regulates mesothelioma proliferation and invasiveness. Oncogene 2011, 30:1643-1652.
19. Ou W.B., Hubert C., Corson J.M., Bueno R., Flynn D.L., Sugarbaker D.J., et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 2011, 13:12-22.
20. Kondo T., Seike M., Mori Y., Fujii K., Yamada T., Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics 2003, 3:1758-1766.
21. Kondo T., Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 2006, 1:2940-2956.
22. Hatakeyama H., Kondo T., Fujii K., Nakanishi Y., Kato H., Fukuda S., et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 2006, 6:6300-6316.
23. Orimo T., Ojima H., Hiraoka N., Saito S., Kosuge T., Kakisaka T., et al. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology 2008, 48:1851-1863.
24. Uemura N., Nakanishi Y., Kato H., Saito S., Nagino M., Hirohashi S., et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer 2009, 124:2106-2115.
25. Fujii K., Kondo T., Yokoo H., Matsuno Y., Iwatsuki K., Hirohashi S. Protein expression pattern distinguishes different lymphoid neoplasms. Proteomics 2005, 5:4274-4286.
26. Suehara Y., Kondo T., Fujii K., Hasegawa T., Kawai A., Seki K., et al. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics 2006, 6:4402-4409.
27. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
28. Kondo T. Cancer proteome-expression database: Genome Medicine Database of Japan Proteomics. Expert Rev Proteomics 2010, 7:21-27.
29. Higashiyama M., Doi O., Kodama K., Yokouchi H., Kasugai T., Ishiguro S. Influence of cathepsin D expression in lung adenocarcinoma on prognosis: possible importance of its expression in tumor cells and stromal cells, and its intracellular polarization in tumor cells. J Surg Oncol 1997, 65:10-19.
30. Selicharova I., Sanda M., Mladkova J., Ohri S.S., Vashishta A., Fusek M., et al. 2-DE analysis of breast cancer cell lines 1833 and 4175 with distinct metastatic organ-specific potentials: comparison with parental cell line MDA-MB-231. Oncol Rep 2008, 19:1237-1244.
31. Vashishta A., Ohri S.S., Proctor M., Fusek M., Vetvicka V. Ribozyme-targeting procathepsin D and its effect on invasion and growth of breast cancer cells: an implication in breast cancer therapy. Int J Oncol 2007, 30:1223-1230.